DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Veliparib is an investigational drug.
There have been 93 clinical trials for Veliparib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Ovarian Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).
There is one US patent protecting this investigational drug and fifteen international patents.
Recent Clinical Trials for Veliparib
|Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer||Fudan University||Phase 2|
|A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer||AbbVie||Phase 1|
|Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Veliparib||Start Trial||Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|Veliparib||Start Trial||Branched 3-phenylpropionic acid derivatives and their use||BAYER PHARMA AKTIENGESELLSCHAFT (Monheim, DE)||Start Trial|
|Veliparib||Start Trial||Bicyclic compounds and their use as antibacterial agents and .beta.-lactamase inhibitors||FEDORA PHARMACEUTICALS INC. (Edmonton, AB, CA)||Start Trial|
|Veliparib||Start Trial||Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers||Immunomedics, Inc. (Morris Plains, NJ)||Start Trial|
|Veliparib||Start Trial||Substituted urea derivatives and pharmaceutical uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||Start Trial|
|Veliparib||Start Trial||System and method for diagnosis and treatment||Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Veliparib||World Intellectual Property Organization (WIPO)||WO2017035357||2035-08-26||Start Trial|
|Veliparib||European Patent Office||EP3131552||2034-04-16||Start Trial|
|Veliparib||New Zealand||NZ629860||2034-04-16||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|